Two pre­clin­i­cal biotechs rid­ing the IPO wave this week look to raise $466M-plus; Black­stone's Galakatos backs Rea­ta to the tune of $350M

→ These days, there’s vir­tu­al­ly no raise too big for biotech. Case in point: 2 loom­ing IPOs where the ex­ec­u­tive team is sketch­ing out some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.